|
| 37097223 | Comparison of IGLV2-14 light chain sequences of patients with AL amyloidosis or multiple myeloma. | | 2023 |
| 36165988 | In Vivo Repeatability and Multiscanner Reproducibility of MRI Radiomics Features in Patients With Monoclonal Plasma Cell Disorders: A Prospective Bi-institutional Study. | Investigative Radiology | 2023 |
| 36282272 | Single-Nucleotide Variants and Epimutations Induce Proteasome Inhibitor Resistance in Multiple Myeloma. | Clinical Cancer Research | 2023 |
| 36256790 | Deep Learning for Automatic Bone Marrow Apparent Diffusion Coefficient Measurements From Whole-Body Magnetic Resonance Imaging in Patients With Multiple Myeloma: A Retrospective Multicenter Study. | Investigative Radiology | 2023 |
| 36449664 | Dynamic Mutational Landscape of Cerebrospinal Fluid Circulating Tumor DNA and Predictors of Survival after Proton Craniospinal Irradiation for Leptomeningeal Metastases. | Clin Cancer Res | 2023 |
| 37591845 | Resolving the spatial architecture of myeloma and its microenvironment at the single-cell level. | | 2023 |
| 36898378 | The pre-existing TÂ cell landscape determines the response to bispecific TÂ cell engagers in multiple myeloma patients. | | 2023 |
| 37466796 | A patient survey indicates quality of life and progression-free survival as equally important outcome measures in multiple myeloma clinical trials. | | 2023 |
| 36895479 | Editorial: The role of the bone marrow microenvironment in multiple myeloma evolution and therapy. | | 2023 |
| 37390336 | Resolving therapy resistance mechanisms in multiple myeloma by multiomics subclone analysis. | Blood | 2023 |
| 37381752 | Clonal hematopoiesis with and mutations impairs regeneration in autologous stem cell transplant recipients. | | 2023 |
| 37251913 | The Immune Microenvironment in Multiple Myeloma Progression at a Single-cell Level. | | 2023 |
| 37001052 | Test-retest, inter- and intra-rater reproducibility of size measurements of focal bone marrow lesions in MRI in patients with multiple myeloma. | | 2023 |
| 37239846 | Polymorphisms within Autophagy-Related Genes as Susceptibility Biomarkers for Multiple Myeloma: A Meta-Analysis of Three Large Cohorts and Functional Characterization. | Int J Mol Sci | 2023 |
| 37300710 | (Smoldering) multiple myeloma: mismatch between tumor load estimated from bone marrow biopsy at iliac crest and tumor load shown by MRI. | | 2023 |
| 36680428 | Cyclophosphamide etoposide dexamethasone as salvage and bridging therapy in relapsed refractory and extramedullary multiple myeloma. | | 2023 |
| 36608320 | A phase 2 clinical trial of combined BRAF/MEK inhibition for BRAFV600E-mutated multiple myeloma. | Blood | 2023 |
| 36599831 | Implications and prognostic impact of mass spectrometry in patients with newly-diagnosed multiple myeloma. | | 2023 |
| 37493665 | Application of an artificial intelligence-based tool in [F]FDG PET/CT for the assessment of bone marrow involvement in multiple myeloma. | | 2023 |
| 37222527 | Prediction of Bone Marrow Biopsy Results From MRI in Multiple Myeloma Patients Using Deep Learning and Radiomics. | | 2023 |
| 35013207 | Functional dissection of inherited non-coding variation influencing multiple myeloma risk. | Nat Commun | 2022 |
| 35966583 | Reduced splenic uptake on Ga-Pentixafor-PET/CT imaging in multiple myeloma - a potential imaging biomarker for disease prognosis. | Theranostics | 2022 |
| 35385581 | Templated Insertions Are Associated Specifically with BRCA2 Deficiency and Overall Survival in Advanced Ovarian Cancer. | Mol Cancer Res | 2022 |
| 35700034 | Does a Multiple Myeloma Polygenic Risk Score Predict Overall Survival of Patients with Myeloma? | Cancer Epidemiol Biomarkers Prev | 2022 |
| 35640004 | Combining Deep Learning and Radiomics for Automated, Objective, Comprehensive Bone Marrow Characterization From Whole-Body MRI: A Multicentric Feasibility Study. | Investigative Radiology | 2022 |
| 36074126 | Circulating Tumor and Immune Cells for Minimally Invasive Risk Stratification of Smoldering Multiple Myeloma. | Clinical Cancer Research | 2022 |
| 35418122 | Genome-wide meta-analysis of monoclonal gammopathy of undetermined significance (MGUS) identifies risk loci impacting IRF-6. | Blood Cancer J | 2022 |
| 36328040 | Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial. | Lancet Haematol | 2022 |
| 35922426 | The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states. | Nature Communications | 2022 |
| 36400754 | An mTORC1 to HRI signaling axis promotes cytotoxicity of proteasome inhibitors in multiple myeloma. | Cell Death and Disease | 2022 |
| 36252999 | IgE type multiple myeloma exhibits hypermutated phenotype and tumor reactive T cells. | J Immunother Cancer | 2022 |
| 35977111 | Characterizing the role of the immune microenvironment in multiple myeloma progression at a single-cell level. | Blood advances | 2022 |
| 36513657 | Author Correction: Functional dissection of inherited non-coding variation influencing multiple myeloma risk. | Nat Commun | 2022 |
| 36611892 | Investigation of Rare Non-Coding Variants in Familial Multiple Myeloma. | Cells | 2022 |
| 35045690 | Comprehensive genomic analysis of refractory multiple myeloma reveals a complex mutational landscape associated with drug resistance and novel therapeutic vulnerabilities. | Haematologica | 2022 |
| 34725502 | Improved prediction of immune checkpoint blockade efficacy across multiple cancer types. | Nat Biotechnol | 2022 |
| 34839306 | Repeatability and Reproducibility of ADC Measurements and MRI Signal Intensity Measurements of Bone Marrow in Monoclonal Plasma Cell Disorders: A Prospective Bi-institutional Multiscanner, Multiprotocol Study. | Investigative Radiology | 2022 |
| 34471932 | Single- and double-hit events in genes encoding immune targets before and after T cell-engaging antibody therapy in MM. | Blood advances | 2021 |
| 34012133 | The mutagenic impact of melphalan in multiple myeloma. | Leukemia | 2021 |
| 33583942 | Characterization of rare germline variants in familial multiple myeloma. | Blood Cancer J | 2021 |
| 34228109 | Search for AL amyloidosis risk factors using Mendelian randomization. | Blood Adv | 2021 |
| 33668879 | Analyzing Longitudinal wb-MRI Data and Clinical Course in a Cohort of Former Smoldering Multiple Myeloma Patients: Connections between MRI Findings and Clinical Progression Patterns. | Cancers (Basel) | 2021 |
| 33619368 | Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma. | Nature Medicine | 2021 |
| 34092058 | Chromosome 1q21 abnormalities refine outcome prediction in patients with multiple myeloma - a meta-analysis of 2,596 trial patients. | Haematologica | 2021 |
| 33875642 | Germline variants at SOHLH2 influence multiple myeloma risk. | Blood Cancer J | 2021 |
| 34192538 | p53-intact cancers escape tumor suppression through loss of long noncoding RNA Dino. | Cell Reports | 2021 |
| 33597728 | Selective elimination of immunosuppressive T cells in patients with multiple myeloma. | Leukemia | 2021 |
| 34782614 | Author Correction: Germline variants at SOHLH2 influence multiple myeloma risk. | Blood Cancer J | 2021 |
| 34845188 | Subclone-specific microenvironmental impact and drug response in refractory multiple myeloma revealed by single-cell transcriptomics. | Nat Commun | 2021 |
| 34439297 | Therapeutic Advances Propelled by Deciphering Tumor Biology and Immunology-Highlights of the 8th Heidelberg Myeloma Workshop. | Cancers | 2021 |